| Abstract | Triflusal (Aflen, Disgren, Tecnosal, Triflux) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk of haemorrhagic complications. In addition, triflusal plus moderate-intensity anticoagulation has demonstrated efficacy when used as thromboprophylaxis in atrial fibrillation. As such, triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable. |
| Authors | David Murdoch, Greg L Plosker
(Affiliation: Adis International Limited, Auckland, New Zealand.)
|
| Journal | Drugs
(Drugs)
Vol. 66
Issue 5
Pg. 671-92
( 2006)
ISSN: 0012-6667 New Zealand |
| PMID | 16620146
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Platelet Aggregation Inhibitors
- Salicylates
- triflusal
|
| Topics |
- Atrial Fibrillation
(complications, drug therapy)
- Cardiovascular Diseases
(etiology, prevention & control)
- Cerebral Infarction
(drug therapy, prevention & control)
- Drug Interactions
- Humans
- Meta-Analysis as Topic
- Myocardial Infarction
(complications, drug therapy)
- Platelet Aggregation Inhibitors
(adverse effects, pharmacokinetics, therapeutic use)
- Practice Guidelines as Topic
- Randomized Controlled Trials as Topic
- Salicylates
(adverse effects, pharmacokinetics, therapeutic use)
- Thromboembolism
(etiology, prevention & control)
|
